Peptide Science
Structure and molecular mechanism for the peptides on the FDA’s July 2026 compounding-review list — each figure generated directly from the peptide’s amino-acid sequence, each mechanism tied to a primary citation.
Research use onlyBody Protection Compound-157 — a synthetic pentadecapeptide (partial sequence of a human gastric-juice protein).
GEPPPGKPADDAGLV
Angiogenesis via the VEGFR2 pathway
Research reports that BPC-157 promotes the formation of new blood vessels (angiogenesis) in association with activation and up-regulation of vascular endothelial growth factor receptor 2 (VEGFR2), the principal receptor driving endothelial-cell growth and migration.[2]
Interaction with the nitric-oxide (NO) system
Reviews describe BPC-157 as an active modulator of the nitric-oxide system — the eNOS/NO signaling axis governing vascular tone and cytoprotection — proposed to underlie much of its reported cytoprotective activity.[1]
Cell migration via the FAK–paxillin pathway
In cultured tendon fibroblasts, BPC-157 has been reported to increase cell survival, outgrowth, and migration through the focal-adhesion-kinase (FAK)–paxillin signaling pathway that controls cell attachment and movement across the extracellular matrix.[3]
Growth-factor signaling & cytoprotection
Literature and patent reviews describe modulation of several growth-factor and receptor pathways and a broad cytoprotective/stress-response profile, alongside notable stability in gastric juice.[1][4]
The evidence base is predominantly preclinical (in-vitro and animal-model studies); large controlled human trials are lacking, and BPC-157 is not an FDA-approved drug. In July 2026 an FDA advisory committee (PCAC) recommended it be considered for pharmacy compounding — advisory, not yet rule. Reviewers also flag an open safety question: the same pro-angiogenic activity in its reported mechanism warrants careful study in the context of tumor biology.[5]
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010
- Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. doi:10.1007/s12178-025-09990-7
A synthetic peptide based on the actin-binding domain of thymosin β4.
LKKTETQ
G-actin sequestration
Thymosin β4 is the major intracellular G-actin–sequestering protein; the LKKTETQ motif on which TB-500 is based binds monomeric actin and regulates the pool available for filament assembly, influencing cytoskeletal remodeling.[1]
Cell migration & tissue repair
In wound-repair models, thymosin β4 is reported to promote endothelial and keratinocyte migration and angiogenesis — activities attributed to its actin-regulating, cell-motility role, and mapped in part to short active sequences including the actin-binding domain.[1][2]
Modulation of inflammatory signaling
Reviews describe additional reported activities of thymosin β4 and its fragments, including modulation of inflammatory signaling in injury models.[2]
The evidence base is predominantly preclinical (in-vitro and animal models of injury and wound repair); TB-500 is not an FDA-approved drug, and its exact composition varies by supplier (the actin-binding fragment versus full-length thymosin β4). In July 2026 an FDA advisory committee (PCAC) recommended it be considered for pharmacy compounding — an advisory recommendation, not yet rule.
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. doi:10.1016/j.molmed.2005.07.004
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144–2151. doi:10.1096/fj.09-142307
Lysine–Proline–Valine — the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH).
KPV
NF-κB pathway inhibition
Research reports that KPV reduces pro-inflammatory signaling by interfering with the NF-κB pathway — the central transcriptional switch controlling inflammatory gene expression — after entering the cell.[1]
PepT1-mediated uptake
In intestinal epithelial and immune cells, KPV is reported to enter via the peptide transporter PepT1 and act intracellularly to downregulate inflammatory cytokines, a mechanism studied in models of intestinal inflammation.[1]
Melanocortin-derived activity
As an α-MSH fragment, KPV is described as retaining anti-inflammatory activity attributed to the parent hormone while lacking its pigmentary action.[2]
Reported activity is drawn from preclinical cell and animal studies (including models of intestinal inflammation); KPV is not an FDA-approved drug. It was among the six peptides an FDA advisory committee (PCAC) recommended for compounding consideration in July 2026 — an advisory recommendation, not yet rule.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. 2008;29(5):581–602. doi:10.1210/er.2007-0027
A mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA.
MRWQEMGYIFYPRKLR
AMPK activation
MOTS-c is reported to activate AMP-activated protein kinase (AMPK), the cell’s central energy sensor, promoting glucose uptake and metabolic homeostasis in preclinical models.[1]
Nuclear translocation & stress-response genes
Under metabolic stress, MOTS-c has been reported to translocate to the nucleus and, with transcription factors such as NRF2, regulate antioxidant and stress-response gene programs — a rare case of a mitochondrial-encoded peptide acting on nuclear DNA.[2]
Metabolic / exercise-associated signaling
It is described in the literature as an exercise-associated metabolic signal, linked to the folate–methionine and AMPK pathways.[1]
Findings are predominantly preclinical (cell and rodent metabolic models); MOTS-c is not an FDA-approved drug. It was among the six peptides an FDA advisory committee (PCAC) recommended for compounding consideration in July 2026 — an advisory recommendation, not yet rule.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516–524. doi:10.1016/j.cmet.2018.06.008
Alanine–Glutamate–Aspartate–Glycine — a synthetic analog of the pineal peptide epithalamin.
AEDG
Telomerase induction
Research from Khavinson and colleagues reports that Epitalon can induce telomerase activity and telomere elongation in cultured human somatic cells.[1]
Gene-expression / pineal signaling
It is described as a short regulatory peptide proposed to interact with DNA and modulate expression of specific genes, and is studied in the context of pineal and melatonin signaling.[2]
The evidence base is limited and largely originates from a single research group (Khavinson and colleagues); independent replication is sparse, and Epitalon is not an FDA-approved drug. It was among the six peptides an FDA advisory committee (PCAC) recommended for compounding consideration in July 2026 — an advisory recommendation, not yet rule. Claims in this area should be read with appropriate caution.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. doi:10.1023/A:1025493705728
- Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties (review). PubMed PMID 40141333.
A synthetic analog of the ACTH(4–10) fragment, with a C-terminal Pro-Gly-Pro extension.
MEHFPGP
BDNF / TrkB regulation
Research reports that Semax binds in the basal forebrain and increases levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus — key regulators of neuronal survival and plasticity.[1][2]
Neurotrophic & neuromodulatory signaling
It is described as influencing neurotrophin systems and monoaminergic signaling, and as being enzymatically stabilized by its C-terminal Pro-Gly-Pro against rapid peptidase degradation.[1]
Reported activity comes largely from preclinical studies; Semax is registered as a medicine in Russia but is not an FDA-approved drug in the United States. It was among the six peptides an FDA advisory committee (PCAC) recommended for compounding consideration in July 2026 — an advisory recommendation, not yet rule.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108
- Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of BDNF protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82–86. doi:10.1111/j.1471-4159.2006.03658.x